DAFTAR PUSTAKA

Adriyanti, A. R., Elfi, E. F., & Hardisman. (2017). Artikel Penelitian Gambaran Fungsi Ginjal pada Pasien Gagal Jantung dengan Fraksi Ejeksi Menurun dan Fraksi Ejeksi Normal di RSUP Dr. M Djamil Padang. *Jurnal Kesehatan Andalas*, *6*(3), 627–633.

Aeddula., S. H. N. R. (2020). Secondary Hypertension - StatPearls - NCBI Bookshelf. In *StatPearls Publishing LLC.*

American Heart Association. (2016). Health Threats From High Blood Pressure | American Heart Association. In *American Heart Association* (pp. 3–5).

Azad, N., Kathiravelu, A., Minoosepeher, S., Hebert, P., & Fergusson, D. (2011). Gender differences in the etiology of heart failure: A systematic review. *Journal of Geriatric Cardiology*, *8*(1), 15–23. https://doi.org/10.3724/SP.J.1263.2011.00015

Bolívar, J. J. (2013). Essential hypertension: An approach to its etiology and neurogenic pathophysiology. *International Journal of Hypertension*, *2013*. https://doi.org/10.1155/2013/547809

Brandes, R. P. (2014). Endothelial Dysfunction and Hypertension. *Hypertension*, *64*(5), 924–928. https://doi.org/10.1161/HYPERTENSIONAHA.114.03575

Cannone, V., & Burnett, J. C. (2022). Natriuretic Peptides and Blood Pressure Homeostasis: Implications for MANP, a Novel Guanylyl Cyclase a Receptor Activator for Hypertension. *Frontiers in Physiology*, *12*(February), 1–8. https://doi.org/10.3389/fphys.2021.815796

CDC. (2022). *Heart Disease Facts*. CDC.Gov.

Deswal, A., Drazner, M. H., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Sandhu, A. T., Stevenson, L. W., & Vardeny, O. (2022). *2022 AHA / ACC / HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines*. https://doi.org/10.1161/CIR.0000000000001063

Djafri, D., & Hasanah, S. R. (2014). *Meta-Analisis Faktor Risiko Modifiable Penyakit Kardovaskular (Hipertensi, Penyakit Jantung Koroner, dan Stroke) di Asia Tenggara*. 1–88.

Feriyawati, L. (2011). Sirkulasi Koroner. *Fakultas Kedokteran Universitas Sumatera Utara*.

Gabb, G. (2020). What is hypertension? *Australian Prescriber*, *43*(4), 108–109. https://doi.org/10.18773/austprescr.2020.025

Grassi, G. (2021). The Sympathetic Nervous System in Hypertension: Roadmap Update of a Long Journey. *American Journal of Hypertension*, *34*(12), 1247–1254. https://doi.org/10.1093/ajh/hpab124

Harigustian, Y., Dewi, A., & Khoiriyati, A. (2016). Gambaran Karakteristik Pasien Gagal Jantung Usia 45 – 65 Tahun Di Rumah Sakit Pku Muhammadiyah Gamping Sleman. *Indonesian Journal of Nursing Practices*, *1*(1), 55–60. https://doi.org/10.18196/ijnp.1152

Iqbal, A. M., & Jamal, S. F. (2022). Essential Hypertension. *XPharm: The Comprehensive Pharmacology Reference*, 1–6. https://doi.org/10.1016/B978-008055232-3.60057-1

Kemenkes. (2021). Pedomanan Nasional Pelayanan Kedokteran Tata Laksana Hipertensi Dewasa. *Kementerian Kesehatan RI*, 1–85.

Kemenkes RI. (2016). *Profil Penyakit Tidak Menular 2016* (Vol. 53, Issue 9).

Kemp, C. D., & Conte, J. V. (2012). The pathophysiology of heart failure. *Cardiovascular Pathology*, *21*(5), 365–371. https://doi.org/10.1016/j.carpath.2011.11.007

Khasanah, D. N. (2022). the Risk Factors of Hypertension in Indonesia (Data Study of Indonesian Family Life Survey 5). *Journal of Public Health Research and Community Health Development*, *5*(2), 80. https://doi.org/10.20473/jphrecode.v5i2.27923

Komamura, K. (2013). Similarities and differences between the pathogenesis and pathophysiology of diastolic and systolic heart failure. *Cardiology Research and Practice*, *1*(1). https://doi.org/10.1155/2013/824135

Komanduri, S. (2017). Prevalence and risk factors of heart failure in the USA : NHANES 2013 – 2014 epidemiological follow-up study. *Journal of Community Hospital Internal Medicine Perspectives*, *7*(1), 15–20. https://doi.org/10.1080/20009666.2016.1264696

Li, Q., Yon, J., Cai, H., Angeles, C. L., & Angeles, L. (2016). Mechanisms and

Consequences of eNOS Dysfunction in Hypertension. *Journal of Hypertension*, *33*(6), 1128–1136. https://doi.org/10.1097/HJH.0000000000000587.Mechanisms

Lin, Y., & Eacker, A. (2023). Secondary Hypertension. *Chalk Talks in Internal Medicine: Scripts for Clinical Teaching*, 39–43. https://doi.org/10.1007/978-3-030-34814-4_7

Mahottama, A. A., Karmaya, I. N. M., & Muliani, . (2021). Prevalensi Hipertensi Pada Penderita Penyakit Jantung Koroner (Pjk) Di Rsup Sanglah Denpasar Maret – September 2019 Fakultas Kedokteran Universitas Udayana. *E-Jurnal Medika Udayana*, *10*(4), 1. https://doi.org/10.24843/mu.2021.v10.i4.p01

Mentz, R. J., & Blaha, M. J. (2018). Cigarette Smoking and Incident. *Circulation Research*, 2572–2582. https://doi.org/10.1161/CIRCULATIONAHA.117.031912

Mogi, M., Maruhashi, T., Higashi, Y., Masuda, T., Nagata, D., Nagai, M., Bokuda, K., Ichihara, A., Nozato, Y., Toba, A., Narita, K., Hoshide, S., Tanaka, A., Node, K., Yoshida, Y., Shibata, H., Katsurada, K., Kuwabara, M., Kodama, T., … Kario, K. (2022). Update on Hypertension Research in 2021. *Hypertension Research*, *45*(8), 1276–1297. https://doi.org/10.1038/s41440-022-00967-4

Mumpuni, H., Kusumastuti, D. A., Bagaswoto, H. P., & Setianto, B. Y. (2020). Epidemiology , Aetiology and Risk Profile of Heart Failure in a Tertiary Referral Hospital : a Report from the Sardjito Heart Failure Registry. *Acta Cardiologia Indonesiana*, *7*(1), 7–12.

Nadruz, W., Shah, A. M., & Solomon, S. D. (2017). Diastolic Dysfunction and Hypertension. *Medical Clinics of North America*, *101*(1), 7–17. https://doi.org/10.1016/j.mcna.2016.08.013

Nagueh, S. F. (2020). Left Ventricular Diastolic Function: Understanding Pathophysiology, Diagnosis, and Prognosis With Echocardiography. *JACC: Cardiovascular Imaging*, *13*(1), 228–244. https://doi.org/10.1016/j.jcmg.2018.10.038

Naing, P., Forrester, D., & Myint, S. M. (2019). Heart failure with preserved ejection fraction A growing global epidemic. *AJGP*, *48*(7), 465–471.

NIH. (2022, March). *How the Heart Works - The Heart | NHLBI, NIH*. National Heart, Lung, and Blood Institute (NIH).

Niluh, C., Rampengan, S. H., & Jim, E. L. (2016). Gambaran penyakit jantung koroner pada pasien gagal jantung yang menjalani rawat inap di RSUP Prof . Dr . R . D . Kandou Manado. *E-Clinic (ECI)*, *4*(November).

Novriyanti, I. D., Usnizar, F., & Irwan. (2014). Pengaruh Lama Hipertensi Terhadap Penyakit Jantung Koroner di Poliklinik Kardiologi RSUP. Dr. Mohammad Hoesin Palembang 2012. *Jurnal Kedokteran Dan Kesehatan*, *1*, 55–60.

Nowell M. Fine , MD, S. (2022). Heart Failure (HF) : Congestive Heart Failure. *Cardiovascular Disorders - MSD Manual Professional Edition*, *4*, 1–22.

Nuraini, B. (2015). Risk Factors of Hypertension. *J Majority*, *4*(5), 10–19.

Oh, G. C., & Cho, H. (2020). Blood pressure and heart failure. *Clinical Hypertension*, 1–8.

Oparil, S., Acelajado, M. C., Bakris, G. L., Berlowitz, D. R., Cífková, R., Dominiczak, A. F., Grassi, G., Jordan, J., Poulter, N. R., Rodgers, A., & Whelton, P. K. (2018). Hypertension. *Nature Reviews Disease Primers*, *4*. https://doi.org/10.1038/nrdp.2018.14

Paramita, A. A. K. Y., Saraswati, M. R., & Wiryawan, N. (2021). Gambaran Karakteristik Gagal Jantung pada Pasien Diabetes Melitus di RSUP Sanglah Denpasar. *Jurnal Penyakit Dalam Udayana*, *5*(2), 37–45.

Pasaribu, S. (2017). penyakit gagal jantung kongestif (CHF). *Repository.Poltekkes-Denpasar*, *d*(2017), 1–15.

PERKI. (2020). Pedoman Tatalaksana Gagal Jantung 2020. 2nd ed. *Perhimpunan Dokter Spesialis Kardiovaskular Indonesia 2020*, *6*(11), 951–952.

Permatasari, D. R., Rachmawati, E., & Ardianto, E. T. (2019). Hubungan antara Diabetes Mellitus dengan Kejadian Heart Failure Berdasarkan Berkas Rekam Medis. *Manajemen Informasi Kesehatan Indonesia*, 143–146. https://doi.org/10.33560/jmiki.v10i2.455

Rampengan, S. H. (2017). Buku praktis Kardiologi. In *Badan Penerbit Fakultas Kedokteran Universitas Indonesia*.

Rehman, I., & Rehman, A. (2022). *Anatomy, Thorax, Heart - PubMed*. StatPearls

[Internet]. Treasure Island (FL): StatPearls Publishing.

Schwinger, R. H. G. (2021). Pathophysiology of heart failure. *Cardiovascular Diagnosis and Therapy*, *11*(1). https://doi.org/10.21037/CDT-20-302

Siagian, R. (2019). *Gambaran Profil Peresepan Obat pada Pasien Penyakit Jantung Rawan Jalan di RS. Bhayangkara Medan*.

Simmonds, S. J., Cuijpers, I., & Heymans, S. (2020). Cellular and Molecular Di ff erences between HFpEF and HFrEF : A Step Ahead in an Improved. *Cells*, *9*(1), 242.

Tackling G, Borhade MB. Hypertensive Heart Disease. [Updated 2023 Jun 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539800/

Tambuwun, C. F. D., Panda, A. L., & Rampengan, S. H. (2016). Gambaran pasien gagal jantung dengan penyakit hipertensi yang menjalani rawat inap di RSUP Prof. Dr. R. D. Kandou Manado periode September – November 2016. *E-CliniC*, *4*(2). https://doi.org/10.35790/ecl.4.2.2016.14680

Tanai, E., & Frantz, S. (2016). Pathophysiology of heart failure. *Comprehensive Physiology*, *6*(1), 187–214. https://doi.org/10.1002/cphy.c140055

Valerie Elma Tappi, Jeini Ester Nelwan, G. D. K. (2018). HUBUNGAN ANTARA AKTIVITAS FISIK DAN RIWAYAT KELUARGA DENGAN KEJADIAN PENYAKIT JANTUNG KORONER DI BADAN LAYANAN UMUM RUMAH SAKIT UMUM PUSAT PROF. DR. R. D. KANDOU MANADO. *Kesehatan Masyarakat*, *7*.

Volpe, J. K., & Makaryus, A. N. (2022). Anatomy, Thorax, Heart and Pericardial Cavity. *StatPearls*.

WHO. (2023). *Hipertensi*. WHO : Fact Sheets.

Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., Johnson, M. R., Kasper, E. K., Levy, W. C., Masoudi, F. A., McBride, P. E., McMurray, J. J. V., Mitchell, J. E., Peterson, P. N., Riegel, B., … Wilkoff, B. L. (2013). 2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology foundation/american heart association task force on practice guidelines. *Journal of the American College of Cardiology*, *62*(16). https://doi.org/10.1016/j.jacc.2013.05.019

LAMPIRAN

Lampiran 1. Surat Izin Penelitian

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN,
RISET, DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN
FAKULTAS KEDOKTERAN
PROGRAM STUDI SARJANA KEDOKTERAN
Jl. Perintis Kemerdekaan Km. 10 Tamalanrea, Makassar 90245, Telp. (0411) 587436, Fax. (0411) 586297

Nomor : 13769/UN4.6.8/PT.01.04/2023 13 Juni 2023
Lamp : ---
Hal : **Permohonan Izin Penelitian**

Kepada Yth. :
Direktur RSUP Dr. Wahidin Sudirohusodo
Di-
Makassar

Dengan hormat, disampaikan bahwa mahasiswa Program Studi Pendidikan Dokter Fakultas Kedokteran Universitas Hasanuddin di bawah ini :

N a m a : Asilah Nurul Qalbi
N i m : C011201217

bermaksud melakukan penelitian di RSUP Dr. Wahidin Sudirohusodo dengan judul penelitian **"Gambaran Pasien Gagal Jantung Dengan Penyakit Hipertensi Di Pusat Jantung Terpadu RSUP Dr. Wahidin Sudirohusodo Periode 2022-2023"**

Sehubungan hal tersebut kiranya yang bersangkutan dapat diberi izin untuk melakukan Penelitian dalam rangka penyelesaian studinya.

Demikian permohonan kami, atas bantuan dan kerjasamanya disampaikan terima kasih.

Ketua,
Program Studi Sarjana Kedokteran
Fakultas Kedokteran Unhas

dr. Ririn Nislawati, M.Kes.,Sp.M
NIP 198101182009122003

Tembusan Yth :
1. Arsip

Lampiran 2. Surat Izin Instansi kepada Kepala Komisi Etik Penelitian Kesehatan FK Unhas

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN,
RISET, DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN
FAKULTAS KEDOKTERAN
PROGRAM STUDI SARJANA KEDOKTERAN
Jl. Perintis Kemerdekaan Km. 10 Tamalanrea, Makassar 90245, Telp. (0411) 587436, Fax. (0411) 586297

Nomor : 13770/UN4.6.8/KP.06.07/2023 13 Juni 2023
Lamp : ---
Hal : **Pengantar Untuk Mendapatkan Rekomendasi Etik**

Yth :
Ketua Komite Etik Penelitian Kesehatan FK Unhas
Makassar

Dengan hormat, disampaikan bahwa mahasiswa Program Studi Sarjana Kedokteran Fakultas Kedokteran Universitas Hasanuddin di bawah ini :

N a m a : Asilah Nurul Qalbi
N i m : C011201217

bermaksud melakukan penelitian dengan Judul "Gambaran Pasien Gagal Jantung Dengan Penyakit Hipertensi Di Pusat Jantung Terpadu RSUP Dr. Wahidin Sudirohusodo Periode 2022-2023"

Untuk maksud tersebut di atas, kami mohon kiranya yang bersangkutan dapat diberikan surat rekomendasi etik dalam rangka penyelesaian studinya.

Demikian permohonan kami, atas bantuan dan kerjasamanya disampaikan terima kasih.

Ketua,
Program Studi Sarjana Kedokteran
Fakultas Kedokteran Unhas

dr. Ririn Nislawati, M.Kes.,Sp.M
NIP 198101182009122003

Tembusan Yth :
1. Arsip

Lampiran 3. Rekomendasi Persetujuan Etik oleh Komisi Etik Penelitian Kesehatan FK Unhas

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,MMed.PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK
Nomor : 401/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 21 Juni 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23060390	No Sponsor	
Peneliti Utama	**Asilah Nurul Qalbi**	Sponsor	
Judul Peneliti	Gambaran Pasien Gagal Jantung dengan Penyakit Hipertensi di Pusat Jantung Terpadu RSUP Dr. Wahidin Sudirohusodo Periode 2022-2023		
No Versi Protokol	**1**	Tanggal Versi	**13 Juni 2023**
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	[x] Exempted [ ] Expedited [ ] Fullboard Tanggal	Masa Berlaku **21 Juni 2023** sampai **21 Juni 2024**	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 4. Hasil penelitian menggunakan *Microsoft Excel 2021*

	Usia	Klp_Usia	JK	HT	Durasi_HT	Durasi_Hipertensi	Klas_GglJtg	Gagal_Jantung	Riw_Rokok	Riw_DM	Riw_Keluarga
1	68	3	0	1	20	3	HFrEF	3	0	0	0
2	50	2	1	1	10	2	HFrEF	3	0	0	0
3	71	3	0	1	20	3	HFrEF	3	0	0	0
4	26	1	0	1	5	1	HFrEF	3	0	0	0
5	57	2	0	1	10	2	HFrEF	3	0	0	0
6	79	3	0	1	12	3	HFrEF	3	0	0	0
7	51	2	1	1	10	2	HFrEF	3	0	0	0
8	52	2	1	1	14	3	HFrEF	3	0	0	0
9	69	3	1	1	10	2	HFpEF	1	0	0	0
10	41	1	0	1	5	1	HFpEF	1	0	0	0
11	51	2	0	1	10	2	HFmrEF	2	0	0	0
12	63	3	1	1	10	2	HFmrEF	2	0	0	0
13	49	2	1	1	7	2	HFmrEF	2	0	0	0
14	69	3	1	1	20	3	HFmrEF	2	0	0	0
15	73	3	1	1	15	3	HFmrEF	2	0	0	0
16	56	2	0	1	13	3	HFmrEF	2	0	0	0
17	75	3	0	1	30	3	HFrEF	3	0	0	0
18	72	3	1	1	25	3	HFrEF	3	0	0	0
19	54	2	1	1	10	2	HFrEF	3	0	0	0
20	58	2	0	1	12	3	HFrEF	3	0	0	0
21	73	3	0	1	20	3	HFrEF	3	0	0	0
22	47	2	0	1	5	1	HFrEF	3	0	0	0
23	55	2	0	1	6	2	HFpEF	1	0	0	0
24	52	2	1	1	7	2	HFpEF	1	0	0	0
25	51	2	1	1	6	2	HFrEF	3	1	0	0
26	74	3	1	1	20	3	HFrEF	3	1	0	0
27	48	2	1	1	10	2	HFrEF	3	1	0	0
28	52	2	1	1	10	2	HFrEF	3	1	0	0
29	69	3	1	1	15	3	HFrEF	3	1	0	0
30	62	3	1	1	20	3	HFrEF	3	1	0	0
31	66	3	1	1	30	3	HFrEF	3	1	0	0
32	63	3	1	1	20	3	HFrEF	3	1	0	0
33	49	2	1	1	15	3	HFrEF	3	1	0	0
34	76	3	1	1	20	3	HFrEF	3	1	0	0

	Usia	Klp_Usia	JK	HT	Durasi_HT	Durasi_Hipertensi	Klas_GglJtg	Gagal_Jantung	Riw_Rokok	Riw_DM	Riw_Keluarga
35	43	1	1	1	11	3	HFrEF	3	1	0	0
36	64	3	1	1	10	2	HFpEF	1	1	0	0
37	58	2	1	1	10	2	HFpEF	1	1	0	0
38	73	3	1	1	15	3	HFpEF	1	1	0	0
39	63	3	1	1	8	2	HFmrEF	2	1	0	0
40	53	2	1	1	5	1	HFmrEF	2	1	0	0
41	58	2	1	1	10	2	HFmrEF	2	1	0	0
42	62	3	1	1	18	3	HFmrEF	2	1	0	0
43	62	3	1	1	18	3	HFmrEF	2	1	0	0
44	54	2	1	1	10	2	HFmrEF	2	1	0	0
45	48	2	1	1	2	1	HFrEF	3	1	0	0
46	61	3	1	1	10	2	HFrEF	3	1	0	0
47	71	3	1	1	30	3	HFrEF	3	1	0	0
48	76	3	1	1	20	3	HFrEF	3	1	0	0
49	50	2	1	1	13	3	HFrEF	3	1	0	0
50	64	3	1	1	1	1	HFmrEF	2	1	0	0
51	67	3	1	1	15	3	HFmrEF	2	1	0	0
52	58	2	1	1	12	3	HFmrEF	2	1	0	0
53	50	2	0	1	2	1	HFrEF	3	0	1	0
54	65	3	0	1	5	1	HFrEF	3	0	1	0
55	64	3	1	1	5	1	HFrEF	3	0	1	0
56	65	3	0	1	10	2	HFrEF	3	0	1	0
57	77	3	0	1	15	3	HFrEF	3	0	1	0
58	59	2	1	1	14	3	HFrEF	3	0	1	0
59	66	3	1	1	15	3	HFpEF	1	0	1	0
60	67	3	0	1	5	1	HFpEF	1	0	1	0
61	43	1	0	1	11	3	HFmrEF	2	0	1	0
62	65	3	1	1	10	2	HFmrEF	2	0	1	0
63	63	3	0	1	10	2	HFrEF	3	0	1	0
64	61	3	0	1	10	2	HFrEF	3	0	1	0
65	56	2	0	1	7	2	HFrEF	3	0	1	0
66	68	3	1	1	15	3	HFrEF	3	1	1	0
67	54	2	1	1	8	2	HFrEF	3	1	1	0
68	55	2	1	1	10	2	HFrEF	3	1	1	0

	Usia	Klp_Usia	JK	HT	Durasi_HT	Durasi_Hipertensi	Klas_GglJtg	Gagal_Jantung	Riw_Rokok	Riw_DM	Riw_Keluarga
69	61	3	0	1	16	3	HFrEF	3	1	1	0
70	73	3	1	1	20	3	HFmrEF	2	1	1	0
71	57	2	1	1	8	2	HFrEF	3	1	1	0
72	74	3	1	1	25	3	HFrEF	3	1	1	0
73	50	2	1	1	6	2	HFrEF	3	1	1	0
74	68	3	1	1	14	3	HFrEF	3	1	1	0
75	37	1	1	1	5	1	HFmrEF	2	1	1	0
76	65	3	1	1	20	3	HFmrEF	2	1	1	0
77	51	2	1	1	3	1	HFrEF	3	0	0	1
78	59	2	1	1	8	2	HFrEF	3	0	0	1
79	61	3	0	1	10	2	HFrEF	3	0	0	1
80	55	2	1	1	20	3	HFrEF	3	0	0	1
81	63	3	0	1	10	2	HFpEF	1	0	0	1
82	80	3	1	1	30	3	HFmrEF	2	0	0	1
83	72	3	1	1	25	3	HFmrEF	2	0	0	1
84	65	3	1	1	18	3	HFmrEF	2	0	0	1
85	64	3	1	1	14	3	HFmrEF	2	0	0	1
86	47	2	1	1	2	1	HFrEF	3	0	0	1
87	69	3	0	1	15	3	HFrEF	3	0	0	1
88	55	2	0	1	11	3	HFrEF	3	0	0	1
89	57	2	0	1	12	3	HFrEF	3	0	0	1
90	66	3	1	1	10	2	HFrEF	3	0	0	1
91	73	3	0	1	20	3	HFpEF	1	0	0	1
92	57	2	1	1	22	3	HFpEF	1	0	0	1
93	56	2	1	1	6	2	HFmrEF	2	0	0	1
94	65	3	1	1	12	3	HFrEF	3	1	0	1
95	56	2	1	1	1	1	HFrEF	3	1	0	1
96	71	3	1	1	20	3	HFrEF	3	1	0	1
97	42	1	1	1	2	1	HFrEF	3	1	0	1
98	49	2	1	1	12	3	HFrEF	3	1	0	1
99	65	3	1	1	17	3	HFrEF	3	1	0	1
100	64	3	1	1	30	3	HFrEF	3	1	0	1
101	34	1	1	1	5	1	HFrEF	3	1	0	1
102	49	2	1	1	2	1	HFmrEF	2	1	0	1

	Usia	Klp_Usia	JK	HT	Durasi_HT	Durasi_Hipertensi	Klas_GglJtg	Gagal_Jantung	Riw_Rokok	Riw_DM	Riw_Keluarga
103	45	2	1	1	5	1	HFmrEF	2	1	0	1
104	41	1	1	1	12	3	HFmrEF	2	1	0	1
105	71	3	1	1	12	3	HFmrEF	2	1	0	1
106	55	2	1	1	12	3	HFmrEF	2	1	0	1
107	57	2	1	1	15	3	HFmrEF	2	1	0	1
108	46	2	1	1	7	2	HFmrEF	2	1	0	1
109	44	1	1	1	1	1	HFrEF	3	1	0	1
110	63	3	1	1	8	2	HFrEF	3	1	0	1
111	55	2	1	1	8	2	HFrEF	3	1	0	1
112	56	2	1	1	15	3	HFrEF	3	1	0	1
113	57	2	1	1	14	3	HFmrEF	2	1	0	1
114	71	3	1	1	20	3	HFmrEF	2	1	0	1
115	66	3	1	1	12	3	HFrEF	3	0	1	1
116	58	2	0	1	1	1	HFrEF	3	0	1	1
117	62	3	1	1	10	2	HFrEF	3	1	1	1
118	57	2	1	1	8	2	HFrEF	3	1	1	1
119	56	2	1	1	7	2	HFrEF	3	1	1	1
120	52	2	1	1	8	2	HFrEF	3	1	1	1
121	64	3	1	1	12	3	HFrEF	3	1	1	1
122	57	2	1	1	15	3	HFrEF	3	1	1	1
123	61	3	1	1	20	3	HFpEF	1	1	1	1
124	48	2	1	1	2	1	HFmrEF	2	1	1	1
125	60	3	1	1	10	2	HFmrEF	2	1	1	1
126	47	2	1	1	5	1	HFmrEF	2	1	1	1
127	55	2	1	1	15	3	HFmrEF	2	1	1	1
128	61	3	0	1	20	3	HFmrEF	2	0	1	0
129	49	2	1	1	20	3	HFrEF	3	1	0	1
130	58	2	1	1	15	3	HFmrEF	2	1	0	1
131	56	2	0	1	10	2	HFrEF	3	0	1	1
132	48	2	1	1	5	1	HFmrEF	2	1	1	1
133	65	3	1	1	10	2	HFrEF	3	0	0	0
134	62	3	0	1	12	3	HFrEF	3	0	0	0
135	62	3	1	1	10	2	HFpEF	1	0	0	0
136	66	3	1	1	13	3	HFmrEF	2	0	0	0

	Usia	Klp_Usia	JK	HT	Durasi_HT	Durasi_Hipertensi	Klas_GglJtg	Gagal_Jantung	Riw_Rokok	Riw_DM	Riw_Keluarga
137	72	3	1	1	20	3	HFmrEF	2	0	0	0
138	84	3	1	1	25	3	HFrEF	3	0	0	0
139	56	2	0	1	10	2	HFpEF	1	0	0	0
140	49	2	1	1	10	2	HFrEF	3	1	0	0
141	63	3	1	1	15	3	HFmrEF	2	1	0	0
142	69	3	0	1	15	3	HFrEF	3	1	0	0
143	60	3	1	1	15	3	HFrEF	3	1	0	0
144	43	1	0	1	8	2	HFrEF	3	0	1	0
145	50	2	0	1	11	3	HFpEF	1	0	1	0
146	59	2	1	1	6	2	HFrEF	3	1	1	0
147	48	2	1	1	7	2	HFrEF	3	1	1	0
148	60	3	1	1	15	3	HFrEF	3	0	0	1
149	57	2	0	1	2	1	HFrEF	3	0	0	1
150	83	3	1	1	25	3	HFrEF	3	0	0	1
151	61	3	0	1	10	2	HFrEF	3	0	0	1
152	66	3	0	1	10	2	HFpEF	1	0	0	1
153	62	3	0	1	20	3	HFmrEF	2	0	0	1
154	33	1	1	1	2	1	HFrEF	3	1	0	1
155	49	2	1	1	2	1	HFrEF	3	1	0	1
156	29	1	1	1	3	1	HFrEF	3	1	0	1
157	28	1	1	1	3	1	HFrEF	3	1	0	1
158	66	3	1	1	15	3	HFrEF	3	1	0	1
159	49	2	1	1	5	1	HFrEF	3	1	0	1
160	51	2	1	1	10	2	HFpEF	1	1	0	1
161	47	2	1	1	31	3	HFpEF	1	1	0	1
162	58	2	1	1	20	3	HFmrEF	2	1	0	1
163	59	2	1	1	9	2	HFmrEF	2	1	0	1
164	65	3	1	1	12	3	HFrEF	3	1	0	1
165	68	3	1	1	18	3	HFrEF	3	1	0	1
166	43	1	0	1	10	2	HFrEF	3	0	1	1
167	70	3	1	1	20	3	HFpEF	1	0	1	1
168	70	3	0	1	20	3	HFmrEF	2	0	1	1
169	67	3	1	1	15	3	HFrEF	3	0	1	1
170	47	2	1	1	1	1	HFrEF	3	1	1	1
171	51	2	1	1	3	1	HFrEF	3	1	1	1
172	65	3	1	1	15	3	HFrEF	3	1	1	1
173	56	2	1	1	7	2	HFmrEF	2	1	1	1
174	62	3	1	1	20	3	HFrEF	3	1	1	1
175	45	2	1	1	7	2	HFrEF	3	1	1	1
176	73	3	1	1	15	3	HFrEF	3	1	1	1
177	65	3	1	1	16	3	HFrEF	3	1	1	1
178	41	1	1	1	10	2	HFrEF	3	0	0	0
179	57	2	0	1	1	1	HFpEF	1	0	1	0

Lampiran 5. Hasil Tabulasi Data menggunakan SPSS 26

Status Hipertensi * Gagal Jantung Crosstabulation

			Gagal Jantung			
			HFpEF	HFmrEF	HFrEF	Total
Status Hipertensi	Tidak Hipertensi	Count	1	6	24	31
		% within Status Hipertensi	3.2%	19.4%	77.4%	100.0%
		% within Gagal Jantung	4.5%	10.9%	18.0%	14.8%
		% of Total	0.5%	2.9%	11.4%	14.8%
	Hipertensi	Count	21	49	109	179
		% within Status Hipertensi	11.7%	27.4%	60.9%	100.0%
		% within Gagal Jantung	95.5%	89.1%	82.0%	85.2%
		% of Total	10.0%	23.3%	51.9%	85.2%
Total		Count	22	55	133	210
		% within Status Hipertensi	10.5%	26.2%	63.3%	100.0%
		% within Gagal Jantung	100.0%	100.0%	100.0%	100.0%
		% of Total	10.5%	26.2%	63.3%	100.0%

Kelompok Umur * Gagal Jantung Crosstabulation

			Gagal Jantung			
			HFpEF	HFmrEF	HFrEF	Total
Kelompok Umur	18-44 tahun	Count	1	3	11	15
		% within Kelompok Umur	6.7%	20.0%	73.3%	100.0%
		% within Gagal Jantung	4.8%	6.1%	10.1%	8.4%
		% of Total	0.6%	1.7%	6.1%	8.4%
	45-64 tahun	Count	13	32	63	108
		% within Kelompok Umur	12.0%	29.6%	58.3%	100.0%
		% within Gagal Jantung	61.9%	65.3%	57.8%	60.3%
		% of Total	7.3%	17.9%	35.2%	60.3%
	>64 tahun	Count	7	14	35	56
		% within Kelompok Umur	12.5%	25.0%	62.5%	100.0%

	% within Gagal Jantung	33.3%	28.6%	32.1%	31.3%
	% of Total	3.9%	7.8%	19.6%	31.3%
Total	Count	21	49	109	179
	% within Kelompok Umur	11.7%	27.4%	60.9%	100.0%
	% within Gagal Jantung	100.0%	100.0%	100.0%	100.0%
	% of Total	11.7%	27.4%	60.9%	100.0%

Jenis Kelamin * Gagal Jantung Crosstabulation

			Gagal Jantung			
			HFpEF	HFmrEF	HFrEF	Total
Jenis Kelamin	Perempuan	Count	9	6	29	44
		% within Jenis Kelamin	20.5%	13.6%	65.9%	100.0%
		% within Gagal Jantung	42.9%	12.2%	26.6%	24.6%
		% of Total	5.0%	3.4%	16.2%	24.6%
	Laki-laki	Count	12	43	80	135
		% within Jenis Kelamin	8.9%	31.9%	59.3%	100.0%
		% within Gagal Jantung	57.1%	87.8%	73.4%	75.4%
		% of Total	6.7%	24.0%	44.7%	75.4%
Total		Count	21	49	109	179
		% within Jenis Kelamin	11.7%	27.4%	60.9%	100.0%
		% within Gagal Jantung	100.0%	100.0%	100.0%	100.0%
		% of Total	11.7%	27.4%	60.9%	100.0%

Durasi HT * Gagal Jantung Crosstabulation

			Gagal Jantung			
			HFpEF	HFmrEF	HFrEF	Total
Durasi HT	Pendek (1-5 tahun)	Count	3	8	21	32
		% within Durasi HT FIX	9.4%	25.0%	65.6%	100.0%
		% within Gagal Jantung	14.3%	16.3%	19.3%	17.9%
		% of Total	1.7%	4.5%	11.7%	17.9%
	Sedang (6-10 tahun)	Count	10	12	35	57
		% within Durasi HT FIX	17.5%	21.1%	61.4%	100.0%
		% within Gagal Jantung	47.6%	24.5%	32.1%	31.8%
		% of Total	5.6%	6.7%	19.6%	31.8%
	Panjang (>10 tahun)	Count	8	29	53	90
		% within Durasi HT FIX	8.9%	32.2%	58.9%	100.0%
		% within Gagal Jantung	38.1%	59.2%	48.6%	50.3%
		% of Total	4.5%	16.2%	29.6%	50.3%
Total		Count	21	49	109	179
		% within Durasi HT FIX	11.7%	27.4%	60.9%	100.0%
		% within Gagal Jantung	100.0%	100.0%	100.0%	100.0%
		% of Total	11.7%	27.4%	60.9%	100.0%

Riwayat Keluarga * Gagal Jantung Crosstabulation

			Gagal Jantung			
			HFpEF	HFmrEF	HFrEF	Total
Riwayat Keluarga	Tidak Ada Riwayat Keluarga	Count	13	24	57	94
		% within Riwayat Keluarga	13.8%	25.5%	60.6%	100.0%
		% within Gagal Jantung	61.9%	49.0%	52.3%	52.5%
		% of Total	7.3%	13.4%	31.8%	52.5%
	Ada riwayat keluarga	Count	8	25	52	85
		% within Riwayat Keluarga	9.4%	29.4%	61.2%	100.0%
		% within Gagal Jantung	38.1%	51.0%	47.7%	47.5%
		% of Total	4.5%	14.0%	29.1%	47.5%
Total		Count	21	49	109	179
		% within Riwayat Keluarga	11.7%	27.4%	60.9%	100.0%
		% within Gagal Jantung	100.0%	100.0%	100.0%	100.0%
		% of Total	11.7%	27.4%	60.9%	100.0%

Riwayat DM * Gagal Jantung Crosstabulation

			Gagal Jantung			
			HFpEF	HFmrEF	HFrEF	Total
Riwayat DM	Tidak DM	Count	15	36	71	122
		% within Riwayat DM	12.3%	29.5%	58.2%	100.0%
		% within Gagal Jantung	71.4%	73.5%	65.1%	68.2%
		% of Total	8.4%	20.1%	39.7%	68.2%
	DM	Count	6	13	38	57

	% within Riwayat DM	10.5%	22.8%	66.7%	100.0%
	% within Gagal Jantung	28.6%	26.5%	34.9%	31.8%
	% of Total	3.4%	7.3%	21.2%	31.8%
Total	Count	21	49	109	179
	% within Riwayat DM	11.7%	27.4%	60.9%	100.0%
	% within Gagal Jantung	100.0%	100.0%	100.0%	100.0%
	% of Total	11.7%	27.4%	60.9%	100.0%

Riwayat Merokok * Gagal Jantung Crosstabulation

			Gagal Jantung			
			HFpEF	HFmrEF	HFrEF	Total
Riwayat Merokok	Tidak Merokok	Count	15	18	46	79
		% within Riwayat Merokok	19.0%	22.8%	58.2%	100.0%
		% within Gagal Jantung	71.4%	36.7%	42.2%	44.1%
		% of Total	8.4%	10.1%	25.7%	44.1%
	Merokok	Count	6	31	63	100
		% within Riwayat Merokok	6.0%	31.0%	63.0%	100.0%
		% within Gagal Jantung	28.6%	63.3%	57.8%	55.9%
		% of Total	3.4%	17.3%	35.2%	55.9%
Total		Count	21	49	109	179
		% within Riwayat Merokok	11.7%	27.4%	60.9%	100.0%
		% within Gagal Jantung	100.0%	100.0%	100.0%	100.0%
		% of Total	11.7%	27.4%	60.9%	100.0%

Lampiran 7. Biodata Peneliti

Nama Lengkap	: Asilah Nurul Qalbi
Jenis Kelamin	: Perempuan
Program Studi	: Pendidikan Dokter Umum
NIM	: C011201217
Tempat, Tanggal Lahir	: Makassar, 26 Juni 2002
Email	: asilahqalbii26@gmail.com
Agama	: Islam
Alamat	: Griya Harapan Andi Tonro Blok F9
Nomor HP	: 081243142240
Riwayat Pendidikan	:

1. SD Kartika XX-1 Makassar
2. SMP Negeri 3 Makassar
3. SMA Negeri 2 Makassar

Semua data yang saya isi dan cantumkan dalam biodata ini adalah benar dan dapat dipertenaggungjawabkan secara hukum. Demikian biodata ini saya buat dengan sebenar-benarnya untuk dipergunakan sebagaimana mestinya.

Makassar, 19 November 2023

Asilah Nurul Qalbi